Jaydira Del Rivero | Medical Oncology | Best Researcher Award

Published on 19/07/2024 by Shen Awards

Dr. Jaydira Del Rivero | Medical Oncology | Best Researcher Award

MD of NCI/NIH, United States.

Professional Profiles:

Education

Dr. Jaydira Del Rivero earned her Doctor of Medicine (MD) degree from the University of Veracruz, Faculty of Medicine “Lic. Miguel Aleman Valdez” in October 2003. She completed her Internal Medicine residency at Woodhull Medical and Mental Health Center/NYU Langone Medical Center in Brooklyn, NY, from July 2008 to June 2011. Following this, she pursued a fellowship in Endocrinology, Diabetes, and Metabolism at the Inter-Institute Adult Endocrine Training Program at the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, from July 2011 to June 2014. Dr. Del Rivero further specialized in Medical Oncology through a fellowship at the National Cancer Institute, National Institutes of Health, Bethesda, MD, from July 2015 to June 2017. Her extensive training reflects her deep commitment to advancing in both endocrinology and oncology.

Professional Experience

Dr. Jaydira Del Rivero has held several notable positions in the medical field. She began her career as a Medical Officer at the National Institute of Child Health and Human Development from August 2014 to June 2015, where she focused on endocrine research. Following her fellowship in Medical Oncology, she joined the National Cancer Institute (NCI) as a Clinical Fellow in the Medical Oncology Branch from July 2015 to June 2017. Since 2017, Dr. Del Rivero has been a Medical Oncologist at the NCI, specializing in the treatment and research of cancer. Her role involves clinical practice, patient management, and contributing to ongoing research efforts. Dr. Del Rivero’s work is pivotal in advancing the understanding and treatment of oncology-related conditions.

Research Interest

Dr. Jaydira Del Rivero’s research interests are centered around oncology, with a particular focus on advancing the understanding and treatment of cancer. Her work primarily explores endocrine-related malignancies, including the development of novel therapeutic strategies and treatment protocols. Dr. Del Rivero is involved in researching the mechanisms of cancer progression and resistance to treatments, aiming to improve patient outcomes through innovative approaches. Her research also encompasses the evaluation of new drugs and treatment regimens, with a commitment to integrating clinical findings with experimental data to enhance therapeutic efficacy. Through her work at the National Cancer Institute, she contributes to cutting-edge studies that aim to address critical challenges in cancer care and therapy.

Award and Honors

Dr. Jaydira Del Rivero has received several notable awards and honors for her contributions to oncology research. She was recognized with the prestigious NCI Director’s Award in 2021 for her exceptional work in cancer research and her commitment to advancing treatment options. In 2019, she earned the American Association for Cancer Research (AACR) Scholar Award, which acknowledged her innovative research on endocrine-related cancers. Additionally, Dr. Del Rivero was honored with the National Cancer Institute’s Outstanding Research Award in 2018 for her impactful studies on novel therapeutic strategies. Her achievements reflect her dedication to improving cancer care and her significant contributions to the field of oncology.

Research Skills

Dr. Jaydira Del Rivero possesses advanced research skills essential for her work in oncology. She is proficient in various laboratory techniques including cell culture, immunohistochemistry, and molecular cloning. Her expertise extends to cutting-edge methods such as CRISPR/Cas9 gene editing and advanced microscopy techniques. Dr. Del Rivero is skilled in data analysis and statistical software such as SPSS and R, which she utilizes for interpreting complex research data. She also has experience with bioinformatics tools for genomic data analysis, enabling her to identify novel biomarkers and therapeutic targets. Her research skills are complemented by a strong ability to design and conduct experiments, critically evaluate scientific literature, and effectively communicate findings through publications and presentations.

Publications

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
Authors: E Wong, LS Rosen, M Mulay, A VanVugt, M Dinolfo, C Tomoda, …
Journal: Thyroid
Year: 2007
Volume/Issue: 17 (4), 351-355
Citations: 238
The Bethesda handbook of clinical oncology
Authors: J Abraham, JL Gulley
Publisher: Lippincott Williams & Wilkins
Year: 2022
Citations: 158
Anti–PD-L1 treatment induced central diabetes insipidus
Authors: C Zhao, SH Tella, J Del Rivero, A Kommalapati, I Ebenuwa, J Gulley, …
Journal: The Journal of Clinical Endocrinology & Metabolism
Year: 2018
Volume/Issue: 103 (2), 365-369
Citations: 104
Tyrosine kinase inhibitor–induced thyroid disorders: a review and hypothesis
Authors: N Makita, T Iiri
Journal: Thyroid
Year: 2013
Volume/Issue: 23 (2), 151-159
Citations: 99
Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors
Authors: AM Rosenberg, P Friedmann, J Del Rivero, SK Libutti, AM Laird
Journal: Surgery
Year: 2016
Volume/Issue: 159 (1), 302-310
Citations: 93
Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis‐hyperphosphatemia syndrome
Authors: MS Ramnitz, P Gourh, R Goldbach‐Mansky, F Wodajo, S Ichikawa, …
Journal: Journal of Bone and Mineral Research
Year: 2016
Volume/Issue: 31 (10), 1845-1854
Citations: 87
The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma
Authors: L Fishbein, J Del Rivero, T Else, JR Howe, SL Asa, DL Cohen, PLM Dahia, …
Journal: Pancreas
Year: 2021
Volume/Issue: 50 (4), 469-493
Citations: 77
Novel insights into the polycythemia–paraganglioma–somatostatinoma syndrome
Authors: R Därr, J Nambuba, J Del Rivero, I Janssen, M Merino, M Todorovic, …
Journal: Endocrine-Related Cancer
Year: 2016
Volume/Issue: 23 (12), 899-908
Citations: 76
Endocrine‐related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management
Authors: J Del Rivero, LM Cordes, J Klubo‐Gwiezdzinska, RA Madan, LK Nieman, …
Journal: The Oncologist
Year: 2020
Volume/Issue: 25 (4), 290-300
Citations: 72
Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report
Authors: JE Faris, AF Moore, GH Daniels
Journal: Thyroid
Year: 2007
Volume/Issue: 17 (11), 1147-1149
Citations: 72

Mohammed Kashani-Sabet | Oncology | Best Researcher Award

Published on 10/04/2024 by Shen Awards

Dr. Mohammed Kashani-Sabet | Oncology | Best Researcher Award

Medical Director, Oncology Service Line, Sutter Health at California Pacific Medical Center Research Institute, United States.

Dr. Mohammed Kashani-Sabet is a distinguished medical professional with extensive expertise in dermatology and oncology. Holding multiple leadership positions, including Medical Director of the Oncology Service Line at Sutter Health and the Cancer Center at California Pacific Medical Center, he has made significant contributions to cancer research and treatment. Dr. Kashani-Sabet received his medical education from renowned institutions such as Harvard University and the State University of New York at Stony Brook. Throughout his career, he has been involved in groundbreaking research focused on melanoma, cutaneous T-cell lymphoma, targeted therapy, and tumor biomarkers. He has received numerous honors and awards for his contributions to the field, including the Clinical Career Development Award from the Dermatology Foundation and the Patients’ Choice Award by Sutter Medical Network. Dr. Kashani-Sabet’s dedication to improving patient care and advancing cancer treatment has earned him widespread recognition and respect in the medical community.

Professional Profiles:

Education:

Dr. Mohammed Kashani-Sabet embarked on his academic journey with a Bachelor’s degree in Biochemical Sciences from Harvard University, followed by a Doctorate in Medicine from the State University of New York at Stony Brook. After completing his medical education, he undertook an internship in Internal Medicine and residency in Dermatology at the State University of New York at Stony Brook and the University of California, San Francisco (UCSF) respectively. Dr. Kashani-Sabet further honed his expertise through a post-doctoral fellowship in Cutaneous Oncology at UCSF’s Department of Dermatology and Division of Hematology/Oncology. This comprehensive educational background laid a robust foundation for his subsequent career as a renowned physician and researcher in the field of dermatology and oncology.

Professional Experience:

Dr. Mohammed Kashani-Sabet has held several prestigious positions throughout his career, demonstrating his leadership and expertise in the field of dermatology and oncology. Currently, he serves as the Medical Director of the Oncology Service Line at Sutter Health and as the Medical Director of the Cancer Center at California Pacific Medical Center. Additionally, he holds the position of Medical Director of the Center for Melanoma Research and Treatment at Sutter West Bay Medical Group, Sutter Pacific Medical Foundation, and California Pacific Medical Center. Dr. Kashani-Sabet also contributes significantly to research as a Senior Scientist at the California Pacific Medical Center Research Institute. His extensive professional experience spans over two decades and encompasses various roles in academia, clinical practice, and administrative leadership within prestigious institutions such as the University of California, San Francisco (UCSF) and the California Pacific Medical Center.

Research Focus:

Dr. Mohammed Kashani-Sabet’s research focus encompasses a broad spectrum of topics within dermatology and oncology, with a particular emphasis on melanoma and cutaneous T-cell lymphoma. His work includes investigating novel targeted therapies, such as ribozymes and siRNAs, for these malignancies. Additionally, he explores tumor metastasis, prognostic modeling, and tumor biomarkers to advance our understanding of these diseases and improve patient outcomes. Dr. Kashani-Sabet’s research efforts aim to translate scientific discoveries into clinical applications, with the ultimate goal of developing more effective treatments and interventions for patients with melanoma and cutaneous T-cell lymphoma.

Research Interest:

Dr. Mohammed Kashani-Sabet possesses a diverse set of research skills honed over years of experience in dermatology and oncology. His expertise includes clinical research, where he designs and conducts studies to evaluate novel therapies for melanoma and cutaneous T-cell lymphoma. In the laboratory, he is skilled in various techniques such as PCR, DNA sequencing, and gene expression analysis, essential for basic and translational research. Dr. Kashani-Sabet also excels in data analysis, utilizing statistical methods and software to interpret clinical and experimental data effectively. With a track record of publishing research findings in peer-reviewed journals, he demonstrates proficiency in scientific writing and manuscript preparation. Additionally, his ability to write grant proposals and collaborate with interdisciplinary teams underscores his commitment to advancing dermatologic oncology research and improving patient care.

Award and Honors:

Dr. Mohammed Kashani-Sabet has been recognized with numerous awards and honors throughout his career, reflecting his exceptional contributions to dermatologic oncology research and patient care. Among these accolades are the Clinical Career Development Award from the Dermatology Foundation in 1997 and the Herschel and Diana Zackheim Endowed Chair in Cutaneous Oncology in the same year. His dedication to teaching and mentorship was acknowledged with the Teacher of the Year Award in 2004, bestowed upon him by the Dermatology Residents at UCSF. Notably, Dr. Kashani-Sabet received the Patients’ Choice Award in 2013 from the Sutter Medical Network for achieving high patient satisfaction scores. His humanitarian efforts were recognized with the Humanitarian Award by the Melanoma Research Foundation in 2014. Moreover, he holds the Chair in Melanoma Research and Treatment at California Pacific Medical Center since 2015, a testament to his leadership and contributions to the field.

Publications:

Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
- Authors: Chang, S.H., Ice, R.J., Chen, M., … Soroceanu, L., McAllister, S.D.
- Citations: 0
- Year: 2023
Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing
- Authors: Kashani-Sabet, M., Leachman, S.A., Stein, J.A., … Venna, S., Kirkwood, J.M.
- Citations: 6
- Year: 2023
Improving Selection for Sentinel Lymph Node Biopsy among Patients with Melanoma
- Authors: Miller, J.R., Lo, S.N., Nosrati, M., … Scolyer, R.A., Kashani-Sabet, M.
- Citations: 3
- Year: 2023
Erratum: Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma
- Authors: Dar, A.A., Bezrookove, V., Nosrati, M., … McAllister, S., Kashani-Sabet, M.
- Citations: 0
- Year: 2023
Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment
- Authors: Sidorov, M., Dighe, P., Woo, R.W.L., … McAllister, S.D., Soroceanu, L.
- Citations: 7
- Year: 2023
Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas
- Authors: Minor, D.R., Kim, K.B., Karuturi, R.K.M., Kashani-Sabet, M.
- Citations: 0
- Year: 2023
Lymphoscintigraphy Using Tilmanocept Detects Multiple Sentinel Lymph Nodes in Melanoma Patients
- Authors: Balkin, D.M., Tranah, G.J., Wang, F., … Zager, J.S., Leong, S.P.
- Citations: 0
- Year: 2023
BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target
- Authors: Bezrookove, V., Khan, I.A., Nosrati, M., … Dar, A.A., Kashani-Sabet, M.
- Citations: 3
- Year: 2022
Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience
- Authors: Chen, M., Jian, D., Sidorov, M., … McAllister, S.D., Desprez, P.-Y.
- Citations: 2
- Year: 2022
Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma
- Authors: Dar, A.A., Bezrookove, V., Nosrati, M., … McAllister, S., Kashani-Sabet, M.
- Citations: 3
- Year: 2022